| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Spotlight on Molecular Profiling
Mutation analysis of 24 known cancer genes in the NCI-60 cell line set
1 1Cancer Genome Project, Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom; 2Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, National Cancer Institute, Bethesda, Maryland; and 3Institute of Cancer Research, Sutton, Surrey, United Kingdom
* To whom correspondence should be addressed. E-mail: mrs{at}sanger.ac.uk.
 |
Abstract |
|---|
The panel of 60 human cancer cell lines (the NCI-60) assembled by the National Cancer Institute for anticancer drug discovery is a widely used resource. The NCI-60 has been characterized pharmacologically and at the molecular level more extensively than any other set of cell lines. However, no systematic mutation analysis of genes causally implicated in oncogenesis has been reported. This study reports the sequence analysis of 24 known cancer genes in the NCI-60 and an assessment of 4 of the 24 genes for homozygous deletions. One hundred thirty-seven oncogenic mutations were identified in 14 (APC, BRAF, CDKN2, CTNNB1, HRAS, KRAS, NRAS, SMAD4, PIK3CA, PTEN, RB1, STK11, TP53, and VHL) of the 24 genes. All lines have at least one mutation among the cancer genes examined, with most lines (73%) having more than one. Identification of those cancer genes mutated in the NCI-60, in combination with pharmacologic and molecular profiles of the cells, will allow for more informed interpretation of anticancer agent screening and will enhance the use of the NCI-60 cell lines for molecularly targeted screens. [Mol Cancer Ther 2006;5(11):2606-12]
Key Words: cancer, NCI-60, cell line, gene, DNA sequence, mutation
This article has been cited by other articles:
|
|
 |
|
  C. A. Pratilas, A. J. Hanrahan, E. Halilovic, Y. Persaud, J. Soh, D. Chitale, H. Shigematsu, H. Yamamoto, A. Sawai, M. Janakiraman, et al. Genetic Predictors of MEK Dependence in Non-Small Cell Lung Cancer Cancer Res., November 15, 2008; 68(22): 9375 - 9383. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hu and A. E. Aplin Skp2 Regulates G2/M Progression in a p53-dependent Manner Mol. Biol. Cell, November 1, 2008; 19(11): 4602 - 4610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hucl, C. Rago, E. Gallmeier, J. R. Brody, M. Gorospe, and S. E. Kern A Syngeneic Variance Library for Functional Annotation of Human Variation: Application to BRCA2 Cancer Res., July 1, 2008; 68(13): 5023 - 5030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O. N. Ikediobi, M. Reimers, S. Durinck, P. E. Blower, A. P. Futreal, M. R. Stratton, and J. N. Weinstein In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation Mol. Cancer Ther., June 1, 2008; 7(6): 1337 - 1346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Hassig, K. T. Symons, X. Guo, P.-M. Nguyen, T. Annable, P. L. Wash, J. E. Payne, D. A. Jenkins, C. Bonnefous, C. Trotter, et al. KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo Mol. Cancer Ther., May 1, 2008; 7(5): 1054 - 1065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. B. Pearson, A. McCarthy, C. M.P. Collins, A. Ashworth, and A. R. Clarke Lkb1 Deficiency Causes Prostate Neoplasia in the Mouse Cancer Res., April 1, 2008; 68(7): 2223 - 2232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Benedetti, P. Perego, G. Luca Beretta, E. Corna, S. Tinelli, S. C. Righetti, R. Leone, P. Apostoli, C. Lanzi, and F. Zunino Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds Mol. Cancer Ther., March 1, 2008; 7(3): 679 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Potapova, A. M. Hoffman, A. K. Godwin, T. Al-Saleem, and P. Cairns Promoter Hypermethylation of the PALB2 Susceptibility Gene in Inherited and Sporadic Breast and Ovarian Cancer Cancer Res., February 15, 2008; 68(4): 998 - 1002. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Ruhe, S. Streit, S. Hart, C.-H. Wong, K. Specht, P. Knyazev, T. Knyazeva, L. S. Tay, H. L. Loo, P. Foo, et al. Genetic Alterations in the Tyrosine Kinase Transcriptome of Human Cancer Cell Lines Cancer Res., December 1, 2007; 67(23): 11368 - 11376. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Liu, X. Wu, W. Zhang, R. C. Montenegro, D. L. Fackenthal, J. A. Spitz, L. M. Huff, F. Innocenti, S. Das, E. H. Cook, Jr., et al. Relationship of EGFR Mutations, Expression, Amplification, and Polymorphisms to Epidermal Growth Factor Receptor Inhibitors in the NCI60 Cell Lines Clin. Cancer Res., November 15, 2007; 13(22): 6788 - 6795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yin, C. Pollock, K. Tracy, M. Chock, P. Martin, M. Oberst, and K. Kelly Activation of the RalGEF/Ral Pathway Promotes Prostate Cancer Metastasis to Bone Mol. Cell. Biol., November 1, 2007; 27(21): 7538 - 7550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Covell, R. Huang, and A. Wallqvist Anticancer medicines in development: assessment of bioactivity profiles within the National Cancer Institute anticancer screening data Mol. Cancer Ther., August 1, 2007; 6(8): 2261 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. Blower, J. S. Verducci, S. Lin, J. Zhou, J.-H. Chung, Z. Dai, C.-G. Liu, W. Reinhold, P. L. Lorenzi, E. P. Kaldjian, et al. MicroRNA expression profiles for the NCI-60 cancer cell panel Mol. Cancer Ther., May 1, 2007; 6(5): 1483 - 1491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. C. Reinhold, M. A. Reimers, A. K. Maunakea, S. Kim, S. Lababidi, U. Scherf, U. T. Shankavaram, M. S. Ziegler, C. Stewart, H. Kouros-Mehr, et al. Detailed DNA methylation profiles of the E-cadherin promoter in the NCI-60 cancer cells Mol. Cancer Ther., February 1, 2007; 6(2): 391 - 403. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
